Navigation Links
ViroPharma to Participate in Several Upcoming Healthcare Investor Conferences
Date:10/29/2010

EXTON, Pa., Oct. 29 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that William Roberts, vice president, corporate communications of ViroPharma, will present at the Oppenheimer 21st Annual Healthcare Conference at 3:55 P.M. ET on Tuesday, November 2, 2010.  The conference is being held at the Waldorf=Astoria in New York City.

Charles Rowland, vice president and chief financial officer, of ViroPharma, will present at the Lazard Capital Markets 7th Annual Healthcare Conference at 1:45 P.M. ET on Wednesday, November 17, 2010.  The conference is being held at the St. Regis Hotel in New York City.

Mr. Rowland will also present at the 4th Annual Maxim Group Growth Conference at 9:30 A.M. ET on Thursday, November 18, 2010.  The conference is being held at the Grand Hyatt in New York City.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze™ (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx).  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
2. ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010
3. ViroPharma to Present at the Jefferies 2010 Global Healthcare Conference
4. ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
5. ViroPharma To Participate in Two September Healthcare Investor Conferences
6. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
7. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
8. ViroPharma to Participate in Two June Healthcare Investor Conferences
9. ViroPharma To Host Investor Day
10. ViroPharma to Participate in the Cowen and Company 30th Annual Healthcare Conference
11. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... NEW YORK , April 19, 2017 ... Surgical drainage devices are tubes used to remove excess ... include, blood, serum, pus, urine, bile or lymph. Surgical ... types of surgery such as orthopedics surgery, cardiovascular surgery, ... device is prophylactic post-surgery to prevent accumulation of fluid ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
(Date:4/19/2017)... 2017  New research provides evidence that an old drug ... a study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... Parkinson,s disease, the oral drug levodopa has long been considered ... as the disease progresses, the effects of the medication can ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... 24, 2017 , ... symplrTM, a leading provider of software ... Kyle Allain has joined the company as Vice President and General Manager of ... payor and managed care solutions. , A seasoned executive with more than ...
(Date:4/24/2017)... ... 2017 , ... MAP Health Management announced today a strategic ... addiction who are served by MAP’s patient engagement ecosystem. Lief Therapeutics is the ... and breath rates to identify anxiety levels and can provide biofeedback exercises to ...
(Date:4/24/2017)... LOS ANGELES, CA (PRWEB) , ... April 24, 2017 , ... ... a picture is worth a thousand words. The good news for single women is ... Journey for Attraction," which is available on April 25th. Joan's insight, personal experiences and ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads all sorts ... any of them to be very practical. She wanted to write a guide/workbook that ... in their health. It prompted her in writing “ A Clear Path to a ...
(Date:4/24/2017)... ... April 24, 2017 , ... “Learning to Use Your ... life. “Learning to Use Your SPIRITUAL COMPASS To Navigate Life Issues” is the ... nonprofits, former Chairman of the Board of Directors for CONTACT USA, and former member ...
Breaking Medicine News(10 mins):